Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase NA 3Phase 3 2Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Rhabdoid Tumor 2Medulloblastoma 2Ependymoma 2Brain Neoplasms 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurotoxicity Syndromes 1Muscle Invasive Bladder Urothelial Carcinoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Large Granular Lymphocytic 1Central Nervous System Neoplasms 1Burkitt Lymphoma 1

Interventions

motexafin gadolinium 1irinotecan sucrosofate 1bemcentinib 1Vincristine 1Temozolomide 1Rituximab 1Radiotherapy 1Radiation 1Procarbazine 1Postoperative Period 1Pemetrexed 1Nivolumab 1Methotrexate 1Memantine 1Irinotecan 1Immunotherapy 1Donepezil 1Cytarabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Central Nervous System Neoplasms × Methotrexate × Clear all
NCT00734773 2012-05-18

Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL

Northwestern University

Phase EARLY_PHASE1 Withdrawn
CNSLymphoid

Lymphoma, Central Nervous System Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡